{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T09:04:51Z","timestamp":1777712691172,"version":"3.51.4"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Astellas Pharma Singapore Pty Ltd"},{"DOI":"10.13039\/100005565","name":"Janssen Global","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Urogenital and Prostate"},{"name":"Cancer Trials Group"},{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","award":["2016274"],"award-info":[{"award-number":["2016274"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The use of surrogate outcomes to support treatment efficacy and cost-effectiveness in localized prostate cancer has the potential to shorten time to access for new medicines, but it may be associated with greater uncertainty. We sought to understand how members of society might trade off drug efficacy, safety, cost-effectiveness, and evidence strength when asked to consider funding new treatments for localized prostate cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A discrete choice experiment among the Australian general population was conducted. Treatment choices were described by cost-effectiveness, government cost, adverse events, patients expected to benefit from treatment, nature of benefits, completeness of data available, and the extent of follow-up. Responses were analyzed using mixed logit and latent class models to assess heterogeneity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The survey was completed by 1003 participants. Respondents favored interventions that benefited a high proportion of patients (OR\u2009=\u20092.44, 95% CI = 2.10 to 2.69), were cost-effective (OR\u2009=\u20090.89, 95% CI = 0.82 to 0.98), low cost to government (OR = 0.75, 95% CI = 0.68 to 0.82), and with long follow-up time (OR = 1.25, 95% CI = 1.12 to 1.39). Respondents showed aversion to ongoing studies (OR = 0.81, 95% CI = 0.75 to 0.88). Respondents were willing to accept less certain evidence if associated with a lower cost-effectiveness ratio (ICER). Latent class analysis revealed 2 subgroups with different preference patterns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The analysis found preference for interventions with maximum benefits while minimizing costs. Respondents preferred studies with longer follow-up time for reimbursement decisions despite consequent treatment delays. Notably, respondents were willing to accept the uncertainty associated with surrogate outcomes\u2014reflected through study length and completeness of evidence\u2014provided the intervention demonstrated a favorable ICER.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jnci\/djaf315","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:09:58Z","timestamp":1761743398000},"page":"429-436","source":"Crossref","is-referenced-by-count":1,"title":["What matters to society when making decisions about reimbursing drugs for prostate cancer: a discrete choice experiment"],"prefix":"10.1093","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4531-8130","authenticated-orcid":false,"given":"Rafael Emilio","family":"De Feria Cardet","sequence":"first","affiliation":[{"name":"CHERE, University of Technology Sydney , Sydney, NSW,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6611-6565","authenticated-orcid":false,"given":"Stephen","family":"Goodall","sequence":"additional","affiliation":[{"name":"CHERE, University of Technology Sydney , Sydney, NSW,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5182-9092","authenticated-orcid":false,"given":"Tracey-Lea","family":"Laba","sequence":"additional","affiliation":[{"name":"CHERE, University of Technology Sydney , Sydney, NSW,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9726-3063","authenticated-orcid":false,"given":"Marion","family":"Haas","sequence":"additional","affiliation":[{"name":"CHERE, University of Technology Sydney , Sydney, NSW,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9066-8244","authenticated-orcid":false,"given":"Ian D","family":"Davis","sequence":"additional","affiliation":[{"name":"Eastern Health, Monash University , Melbourne, VIC,","place":["Australia"]},{"name":"Eastern Health Clinical School, Monash University , Melbourne, VIC,","place":["Australia"]},{"name":"ANZUP Cancer Trials Group , Sydney, NSW,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4476-0656","authenticated-orcid":false,"given":"Deborah J","family":"Street","sequence":"additional","affiliation":[{"name":"CHERE, University of Technology Sydney , Sydney, NSW,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0398-6018","authenticated-orcid":false,"given":"Christopher J","family":"Sweeney","sequence":"additional","affiliation":[{"name":"South Australian Immunogenomics Cancer Institute, University of Adelaide , Adelaide, SA,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5978-8774","authenticated-orcid":false,"given":"Richard","family":"De Abreu Louren\u00e7o","sequence":"additional","affiliation":[{"name":"CHERE, University of Technology Sydney , Sydney, NSW,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"2026030819563734300_djaf315-B1","doi-asserted-by":"publisher","first-page":"djv261","DOI":"10.1093\/jnci\/djv261","article-title":"The development of intermediate clinical endpoints in cancer of the prostate (ICECaP)","volume":"107","author":"Sweeney","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"2026030819563734300_djaf315-B2","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1200\/JCO.2017.73.9987","article-title":"Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer","volume":"35","author":"Xie","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026030819563734300_djaf315-B3","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1200\/JCO.2023.41.6_suppl.372","article-title":"Societal benefits of surrogate outcomes to support reimbursement decisions: the case of prostate cancer","volume":"41","author":"de Feria Cardet","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026030819563734300_djaf315-B4","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12916-017-0902-9","article-title":"Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?","volume":"15","author":"Kemp","year":"2017","journal-title":"BMC Med"},{"key":"2026030819563734300_djaf315-B5","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1017\/s0266462314000300","article-title":"Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers","volume":"30","author":"Ciani","year":"2014","journal-title":"Int J Technol Assess Health Care"},{"key":"2026030819563734300_djaf315-B6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.socscimed.2015.10.005","article-title":"Attributes and weights in health care priority setting: a systematic review of what counts and to what extent","volume":"146","author":"Gu","year":"2015","journal-title":"Soc Sci Med"},{"key":"2026030819563734300_djaf315-B7","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1586\/14737167.2.4.319","article-title":"Discrete choice experiments to measure consumer preferences for health and healthcare","volume":"2","author":"Viney","year":"2002","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2026030819563734300_djaf315-B8","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","article-title":"Conjoint analysis applications in health\u2014a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force","volume":"14","author":"Bridges","year":"2011","journal-title":"Value Health"},{"key":"2026030819563734300_djaf315-B9","doi-asserted-by":"publisher","first-page":"3544","DOI":"10.1177\/0962280217704226","article-title":"A Bayesian hierarchical model for discrete choice data in health care","volume":"27","author":"Antonio","year":"2018","journal-title":"Stat Methods Med Res"},{"key":"2026030819563734300_djaf315-B10","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/bjc.2013.370","article-title":"Patients\u2019 and urologists\u2019 preferences for prostate cancer treatment: a discrete choice experiment","volume":"109","author":"de Bekker-Grob","year":"2013","journal-title":"Br J Cancer"},{"key":"2026030819563734300_djaf315-B11","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s12325-018-0861-3","article-title":"Patient preferences for metastatic hormone-sensitive prostate cancer treatments: a discrete choice experiment among men in three European countries","volume":"36","author":"de Freitas","year":"2019","journal-title":"Adv Ther"},{"key":"2026030819563734300_djaf315-B12","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.clinthera.2017.02.009","article-title":"Patients\u2019 preferences for the treatment of metastatic castrate-resistant prostate cancer: a discrete choice experiment","volume":"39","author":"Eliasson","year":"2017","journal-title":"Clin Ther"},{"key":"2026030819563734300_djaf315-B13","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/j.1369-7625.2004.00271.x","article-title":"Patient-focussed decision-making in early-stage prostate cancer: insights from a cognitively based decision aid","volume":"7","author":"Feldman-Stewart","year":"2004","journal-title":"Health Expect"},{"key":"2026030819563734300_djaf315-B14","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.urology.2010.10.039","article-title":"Factors that influence patient enrollment in active surveillance for low-risk prostate cancer","volume":"77","author":"Gorin","year":"2011","journal-title":"Urology"},{"key":"2026030819563734300_djaf315-B15","doi-asserted-by":"publisher","first-page":"2381468319855375","DOI":"10.1177\/2381468319855375","article-title":"Patient-centered approach to develop the patient\u2019s preferences for prostate cancer care (PreProCare) tool","volume":"4","author":"Jayadevappa","year":"2019","journal-title":"MDM Policy Prac"},{"key":"2026030819563734300_djaf315-B16","author":"Kaplan"},{"key":"2026030819563734300_djaf315-B17","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/bjc.2011.552","article-title":"Survival gains needed to offset persistent adverse treatment effects in localised prostate cancer","volume":"106","author":"King","year":"2012","journal-title":"Br J Cancer"},{"key":"2026030819563734300_djaf315-B18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/sj.pcan.4500992","article-title":"Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer","volume":"11","author":"Lloyd","year":"2008","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2026030819563734300_djaf315-B19","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1177\/1557988318776123","article-title":"Patient preferences and urologist judgments on prostate cancer therapy in Japan","volume":"12","author":"Nakayama","year":"2018","journal-title":"Am J Mens Health"},{"key":"2026030819563734300_djaf315-B20","doi-asserted-by":"publisher","first-page":"367.e7-367","DOI":"10.1016\/j.urolonc.2020.12.014","article-title":"Patients\u2019 preferences for delaying metastatic castration-resistant prostate cancer: combining health state and treatment valuation","volume":"39","author":"Rentz","year":"2021","journal-title":"Urol Oncol"},{"key":"2026030819563734300_djaf315-B21","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1097\/01.ju.0000181829.07078.22","article-title":"A novel computer based expert decision making model for prostate cancer disease management","volume":"174","author":"Richman","year":"2005","journal-title":"J Urol"},{"key":"2026030819563734300_djaf315-B22","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1136\/bmj.37972.497234.44","article-title":"Patients\u2019 preferences for the management of non-metastatic prostate cancer: discrete choice experiment","volume":"328","author":"Sculpher","year":"2004","journal-title":"BMJ"},{"key":"2026030819563734300_djaf315-B23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12894-020-00631-4","article-title":"Physician preferences for non-metastatic castration-resistant prostate cancer treatment","volume":"20","author":"Srinivas","year":"2020","journal-title":"BMC Urol"},{"key":"2026030819563734300_djaf315-B24","doi-asserted-by":"publisher","first-page":"6586","DOI":"10.1002\/cam4.3321","article-title":"Patient and caregiver benefit-risk preferences for nonmetastatic castration-resistant prostate cancer treatment","volume":"9","author":"Srinivas","year":"2020","journal-title":"Cancer Med"},{"key":"2026030819563734300_djaf315-B25","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1200\/go.20.00358","article-title":"Understanding treatment strategies and preferences in nonmetastatic castration-resistant prostate cancer from the Japanese physician perspective","volume":"7","author":"Suzuki","year":"2021","journal-title":"J Clin Oncol Glob Oncol"},{"key":"2026030819563734300_djaf315-B26","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12894-016-0182-2","article-title":"Patient preferences for treatment of castration-resistant prostate cancer in Japan: a discrete-choice experiment","volume":"16","author":"Uemura","year":"2016","journal-title":"BMC Urol"},{"key":"2026030819563734300_djaf315-B27","doi-asserted-by":"publisher","first-page":"e052471","DOI":"10.1136\/bmjopen-2021-052471","article-title":"Unmet needs in non-metastatic castration-resistant prostate cancer from the Japanese patient perspective: a discrete choice experiment","volume":"11","author":"Uemura","year":"2021","journal-title":"BMJ Open"},{"key":"2026030819563734300_djaf315-B28","first-page":"5346","article-title":"Multiple physician recommendations for prostate cancer treatment: a Pandora\u2019s box for patients?","volume":"17","author":"Underwood","year":"2010","journal-title":"Can J Urol"},{"key":"2026030819563734300_djaf315-B29","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/pon.3444","article-title":"\u201cIt\u2019s not like you just had a heart attack\u201d: decision-making about active surveillance by men with localized prostate cancer","volume":"23","author":"Volk","year":"2014","journal-title":"Psychooncology"},{"key":"2026030819563734300_djaf315-B30","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/JU.0000000000000754","article-title":"Evaluating the trade-offs men with localized prostate cancer make between the risks and benefits of treatments: the COMPARE study","volume":"204","author":"Watson","year":"2020","journal-title":"J Urol"},{"key":"2026030819563734300_djaf315-B31","doi-asserted-by":"crossref","DOI":"10.1002\/9780470148563","volume-title":"The Construction of Optimal Stated Choice Experiments: Theory and Methods","author":"Street","year":"2007"},{"key":"2026030819563734300_djaf315-B32","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1023\/A:1022558715350","article-title":"The mixed logit model: the state of practice","volume":"30","author":"Hensher","year":"2003","journal-title":"Transportation (Amst)"},{"key":"2026030819563734300_djaf315-B33","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1177\/1536867x0700700306","article-title":"Fitting mixed logit models by using maximum simulated likelihood","volume":"7","author":"Hole","year":"2007","journal-title":"Stata J Promot Commun Stat Stata"},{"key":"2026030819563734300_djaf315-B34","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1016\/j.socscimed.2006.12.007","article-title":"Several methods to investigate relative attribute impact in stated preference experiments","volume":"64","author":"Lancsar","year":"2007","journal-title":"Soc Sci Med"},{"key":"2026030819563734300_djaf315-B35","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0191-2615(02)00046-2","article-title":"A latent class model for discrete choice analysis: contrasts with mixed logit","volume":"37","author":"Greene","year":"2003","journal-title":"Transportation Res Part B Methodol"},{"key":"2026030819563734300_djaf315-B36","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1177\/0095798420930932","article-title":"Latent class analysis: a guide to best practice","volume":"46","author":"Weller","year":"2020","journal-title":"J Black Psychol"},{"key":"2026030819563734300_djaf315-B37","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1177\/1536867X20931003","article-title":"lclogit2: an enhanced command to fit latent class conditional logit models","volume":"20","author":"Yoo","year":"2020","journal-title":"Stata J"},{"key":"2026030819563734300_djaf315-B38","author":"Hole","year":"2007"},{"key":"2026030819563734300_djaf315-B39","author":"Australian Bureau of Statistics"},{"key":"2026030819563734300_djaf315-B40","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s40273-017-0586-1","article-title":"Revealed and stated preferences of decision makers for priority setting in health technology assessment: a systematic review","volume":"36","author":"Ghijben","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"2026030819563734300_djaf315-B41","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1017\/S0266462310000048","article-title":"Dear policy maker: have you made up your mind? A discrete choice experiment among policy makers and other health professionals","volume":"26","author":"Koopmanschap","year":"2010","journal-title":"Int J Technol Assess Health Care"},{"key":"2026030819563734300_djaf315-B42","doi-asserted-by":"publisher","first-page":"e0219905","DOI":"10.1371\/journal.pone.0219905","article-title":"What attributes should be included in a discrete choice experiment related to health technologies? A systematic literature review","volume":"14","author":"Trapero-Bertran","year":"2019","journal-title":"PLoS One"},{"key":"2026030819563734300_djaf315-B43","doi-asserted-by":"publisher","first-page":"o1912","DOI":"10.1136\/bmj.o1912","article-title":"Surrogate endpoints in trials\u2014a call for better reporting","volume":"378","author":"Ciani","year":"2022","journal-title":"BMJ"},{"key":"2026030819563734300_djaf315-B44","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.116.005285","article-title":"Two decades of cardiovascular trials with primary surrogate endpoints: 1990-2011","volume":"6","author":"Bikdeli","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2026030819563734300_djaf315-B45","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2165\/11537150-000000000-00000","article-title":"Public and decision maker stated preferences for pharmaceutical subsidy decisions: a pilot study","volume":"9","author":"Whitty","year":"2011","journal-title":"Appl Health Econ Health Policy"},{"key":"2026030819563734300_djaf315-B46","volume-title":"Public Preferences for Health Gains and Cures: a Discrete Choice Experiment. OHE Consulting Report","author":"Hampson","year":"2018"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djaf315\/65132152\/djaf315.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/118\/3\/429\/65132152\/djaf315.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/118\/3\/429\/65132152\/djaf315.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T23:56:44Z","timestamp":1773014204000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/118\/3\/429\/8313527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":46,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,11,3]]},"published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djaf315","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,11,3]]}}}